SPIE and ICFO Announce $1 Million Endowed Diversity-Focused Chair at ICFO
SPIE, the international society for optics and photonics, announced the establishment of the SPIE@ICFO Chair for Diversity in Photonic Sciences with ICFO, the Barcelona-based Institute of Photonic Sciences, a center devoted to the development of research, post-graduate training, and knowledge and technology transfer in fields where optics and photonics play a decisive role. A sum of $500,000 in funding from SPIE is being matched by €500,000 from the existing ICFO endowment. The combined fund will support the appointment of a chair at ICFO whose remit will be to leverage the center’s activities to further enhance its promotion of diversity, starting with its multiple programs supporting the education and careers of young women from diverse backgrounds who have an interest in photonics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005193/en/
ICFONIANS UNITED: Researchers, staff, and students celebrate their logo. The “R” stands for "recerca," the Catalan word for “research." This was part of the original branding of the research institutes established by the government of Catalonia a little over 20 years ago, and ICFO retains it in their logo. (Photo: Business Wire)
The ambition for the SPIE@ICFO chair program goes beyond gender diversity and aims to support a diverse range of ambitious students and researchers in photonic sciences who would otherwise not have such opportunities. Newly supported opportunities will include the SPIE@ICFO Chair María Yzuel Fellowship Award Internships; the SPIE@ICFO Chair Travel Fellowship; and the SPIE@ICFO Chair Research Fellowship.
“This exciting partnership with ICFO beautifully complements our own commitment to enhancing equity, diversity, and inclusion across the optics and photonics community,” said SPIE President John Greivenkamp. “We are delighted to support an education program which will focus on active promotion of a tolerant, welcoming work environment that meets the academic and research needs of a diverse population.”
“We are extremely proud of this long-lasting alliance with SPIE,” said ICFO Director Lluis Torner. “Its visionary endowment program will afford the possibility to launch a unique SPIE@ICFO Chair for Diversity in Photonic Sciences, a topic both organizations consider to be of paramount importance to enhance innovation, creativity, and excellence across the board. I would like to thank SPIE for its outstanding support and our Board of Trustees for making the program possible, and I want to congratulate the Chair and Vice-Chairs, Rob Sewell, Silvia Carrasco, and Laia Miralles, for their appointment.”
The SPIE Endowment Matching Program, established in 2019, is a $2.5 million, five-year, educational-funding initiative designed to increase international capacity in the teaching and research of optics and photonics. SPIE supports optics and photonics education and the future of the industry by contributing up to $500,000 per award to college and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission. The initial SPIE contribution to the University of Arizona named a new endowed faculty chair, the SPIE Chair in Optical Sciences. Three more agreements announced earlier this year established the SPIE-Glebov Family Optics and Photonics Graduate Scholarship Fund and the Soileau Family-SPIE Optics and Photonics Undergraduate Scholarship Fund, both at the University of Central Florida’s (UCF) College of Optics and Photonics (CREOL), and the Baur-SPIE Endowed Chair in Optics and Photonics at JILA.
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 255,000 constituents from 183 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2019, SPIE provided more than $5.6 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org
ICFO – The Institute of Photonic Sciences is an institute dedicated to frontier research in diverse areas in which photonics plays a decisive role, with an emphasis on basic and applied themes relevant to medicine and biology, advanced imaging techniques, information technologies, a range of environmental sensors, tunable and ultra-fast lasers, quantum science, photovoltaics and the properties and applications of nano-materials such as graphene, among others. The institute hosts over 350 researchers from over 60 countries and at all career levels. In addition to its mission to train the next generation of scientists and technologists for careers in academia and industry, ICFO is proactive in fostering entrepreneurial activities and spin-off creation. An active Corporate Liaison Program aims at creating collaborations and links between industry and ICFO researchers. www.icfo.eu
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a